Stay updated on Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.

Latest updates to the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page
- Check3 days agoChange DetectedThe page revision label was updated from v3.6.3 to v3.6.4, indicating a software update. The underlying study information and user-facing content remain unchanged.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedFooter text now includes Moffitt center branding and a new revision tag (v3.6.3). The old revision tag (v3.6.2) was removed.SummaryDifference0.2%

- Check32 days agoChange DetectedThe page's revision tag was updated to v3.6.2 from v3.6.0, signaling a new version of the page metadata. This update reflects documentation/version control activity rather than changes to the study data.SummaryDifference0.0%

- Check46 days agoChange DetectedRecruitment status now indicates no participant enrollment; new sections for How to Read a Study Record, Common Questions, and How to Join a Study were added, and the Intervention/Treatment heading was adjusted with a revision note updated to v3.6.0.SummaryDifference0.4%

- Check53 days agoChange DetectedThe page's revision label updates from v3.5.4 to v3.5.5, indicating a new build/version of the page. This is a minor metadata change that does not alter visible content or functionality.SummaryDifference0.0%

- Check60 days agoChange DetectedSponsor attribution and the credits label are removed from the study page, altering how the page credits its sponsor and provides external links.SummaryDifference0.1%

Stay in the know with updates to Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.